Pericardial effusion under nivolumab: case-reports and review of the literature

Pericardial effusion under nivolumab: case-reports and review of the literature

Abstract Background Nivolumab, a programmed death-1 (PD-1) inhibitor, is an immune checkpoint inhibitor particularly used in the treatment of malignant melanoma, non-small cell lung cancer and renal cell carcinoma. Immune-related adverse events are frequent under immunotherapies. Cardiotoxic side ef...

Full description

Bibliographic Details
Main Authors: Saade Anastasia, Mansuet-Lupo Audrey, Arrondeau Jennifer, Thibault Constance, Mirabel Mariana, Goldwasser François, Oudard Stéphane, Weiss Laurence
Format: Article
Language:English
Published: BMJ Publishing Group 2019-10-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Immune checkpoint inhibitor
Nivolumab
Immune-related adverse event
Pericardial effusion
Tamponade
Cardiotoxicity
Online Access:http://link.springer.com/article/10.1186/s40425-019-0760-4

Internet

http://link.springer.com/article/10.1186/s40425-019-0760-4

Similar Items